Breaking AI & Tech News Analyzed

Scientists from University College London and partners have proved that a 50‑gene genomic test can reliably pinpoint hormone‑positive breast‑cancer patients who do not need chemotherapy, potentially sparing millions from toxic side‑effects.Optima Trial Demonstrates Genomic Test Can Identify Low‑Risk PatientsThe Optima trial enrolled 4,429 women aged 40+ across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Participants were split into a standard‑care arm (chemotherapy + hormone therapy) and a test‑guided arm where treatment was decided by the genomic score.Trial Numbers Reveal Near‑Identical Survival RatesFive‑year outcomes were strikingly similar:95% of patients receiving chemotherapy remained alive and recurrence‑free.94% of patients who skipped chemotherapy (low‑score group) were also alive and recurrence‑free.The test classified patients using a score derived from the activity of 50 tumour genes, produced by Veracyte's Prosigna assay.These figures indicate that for low‑score patients, chemotherapy adds little or no survival benefit.Potential Shift in Breast Cancer Treatment GuidelinesProf Rob Stein, chief investigator, says the results “address a longstanding challenge” by moving decision‑making from clinical features to tumour biology. Health systems could see reduced drug costs, fewer hospital visits, and a dramatic drop in chemotherapy‑related toxicity.Future Adoption and Healthcare SavingsWith funding from the NIHR, Veracyte and cancer charities, the study paves the way for rapid guideline updates at bodies like ASCO and NICE. Wider implementation could translate into billions of dollars saved globally and improve quality of life for countless patients. Ongoing monitoring will confirm long‑term outcomes, but the early data suggest a new era of personalised, cost‑effective breast‑cancer care.

A shock government‑backed report this week warned of the danger of a “lost generation” of young people in Britain, as the number of 16‑ to 24‑year‑olds not in education, employment or training (NEETs) rose to more than 1 million, roughly 13.5% of the cohort.Rising NEET Numbers Spark Alarm in the UKOfficial UK statistics show that 13.5% of young people are not in work or college, climbing to 15.8% among 18‑ to 24‑year‑olds – nearly one in six. The report, authored by former Labour cabinet minister Alan Milburn, warns that without decisive action the country could see a sustained “lost generation”.Comparative NEET Rates: UK vs NetherlandsUK NEET rate (16‑24): 13.5% overall, 15.8% for 18‑24 year olds.Netherlands NEET rate (15‑29, adjusted): 5.3% last year, consistently below 5% for over a decade.Potential impact: Matching the Dutch rate could move 600,000 more 18‑ to 24‑year‑olds into learning or earning.Why Dutch Vocational Pathways Keep Youth EngagedThe Dutch system centres on three pillars: strong vocational secondary education (MBO), a welfare safety net that prioritises engagement and rehabilitation, and financial incentives for employers. Around 70% of Dutch 16‑ to 19‑year‑olds in upper secondary education attend an MBO school, and 35% of under‑25s later study at technical or professional universities. By contrast, only 22% of UK 18‑ to 21‑year‑olds were on vocational courses in 2024.Technical education is treated as “the foundation of the economy”, with work‑based learning embedded in curricula – many students combine four days of school with one day of on‑the‑job training.Policy Levers Behind the Dutch Low NEET RateThe 2004 Work and Social Assistance Act devolved welfare programmes to municipalities, creating personalised, localised support that addresses mental health and long‑term illness. Local councils provide tailored engagement programmes, subsidised employment, and specialised training, preventing young people on incapacity benefits from falling through the cracks.Employers receive fiscal incentives, such as payroll‑tax cuts and direct subsidies that cover up to 70% of wages for chronically unemployed youth, as highlighted by the Youth Futures Foundation. Rotterdam’s city council, led by Tim Versnel, funds up to 70% of wages for young chronically unemployed people and offers holistic support covering mental resilience, substance‑use treatment, and financial literacy.What the UK Could Adopt to Reverse the TrendTo emulate the Dutch success, the UK might consider:Expanding vocational pathways and integrating work‑based learning into secondary education.Devolving youth‑welfare services to local authorities for more personalised support.Introducing targeted fiscal incentives for businesses hiring young workers, including wage subsidies and tax relief.Adopting a whole‑of‑life approach that combines education, mental‑health services, and financial literacy for chronically unemployed youth.While cultural and structural differences mean a direct copy is impossible, the Dutch experience offers a roadmap for reducing Britain’s NEET rate and revitalising its youth labour market.

The Discovery of PFAS in the Solent Strait Scientists have found high levels of toxic PFAS, or “forever chemicals”, in soil, water and throughout the marine food chain in the UK’s Solent strait, including at protected environmental sites, according to a new study. Extent of the Pollution In some samples, pollution was 13 times the safe threshold for coastal waters. Others, which were below legal limits for individual chemicals, failed tests for combined toxicity. The samples were taken from the Solent strait, which runs between the Isle of Wight and the mainland, forming part of the Channel. Sources of the Chemicals The chemicals are thought to have entered the environment from wastewater treatment plants, sewage outflows, historic landfills and nearby military sites. Researchers analysed government data, testing at water utilities, and their own samples from a dozen species of fish, seaweed and invertebrates. Impact on the Environment They found PFAS were entering the Solent in treated effluent from wastewater plants in Portsmouth and Fareham operated by Southern Water, the utility that provides drinking water and sewerage for Kent, Sussex, Hampshire and the Isle of Wight. The study also mapped 194 combined sewer overflow outfalls and more than 500 nearby historic landfills that researchers believe could also contribute to the pollution. Calls for Action Researchers said their findings highlighted the need to monitor chemicals in combination and to make a blanket ban on PFAS part of the government’s water reform agenda. Prof Alex Ford, a biologist at the University of Portsmouth and one of the study’s authors, said: “If there was an oil spill in the Solent that industry would have to pay for the restoration of those habitats, but that doesn’t happen with sewage.” Future Outlook The EU is moving towards a blanket PFAS ban, probably with some exceptions for medicine and other critical uses. The British government said it would consult on setting limits for the chemicals and carry out further tests when its own PFAS plan was published in February, promising a “framework … to understand where these chemicals are coming from, how they spread and how to reduce public and environmental exposure”.

The Comedian Who Refuses to Stay SilentNish Kumar has built a career on being unafraid to speak his mind, even when it means confronting fellow comedians like Jimmy Carr about their decisions to perform in controversial venues. The British stand-up, known for his articulate and politically charged humor, recently discussed his confrontations with comics who participated in the Riyadh comedy festival, calling it part of the "cultural-washing of a repressive regime." Kumar's upcoming tour, "Angry Humour from a Really Nice Guy," reflects his concern that comedy has been "co-opted by charlatans in service of autocrats." Despite his willingness to court controversy, Kumar admits there are moments when he questions his approach, joking that "you should not be allowed to give interviews" when discussing fellow comedians.The Confrontation Over Comedy EthicsKumar's most notable public clash came when he confronted Jimmy Carr about his decision to appear on Jordan Peterson's podcast, which Kumar described as "a radicalisation event that's happening on an unprecedented scale." His criticism extends to other comics who performed in Saudi Arabia, including Bill Burr, Dave Chappelle, and Jack Whitehall. Kumar alleges that some comics "signed a contract agreeing to not have a go at MBS [Mohammed bin Salman, the crown prince of Saudi Arabia]" and expressed particular frustration with those who have complained about cancel culture while participating in such events. "I don't want to hear about free speech from any of these cunts again," he stated emphatically. These confrontations highlight Kumar's commitment to what he sees as ethical boundaries in comedy, even when it means alienating his peers.A Career Forged in Debate and DeterminationNow 40, Kumar has been performing stand-up for two decades, though his love for comedy began much earlier. At age five, he was studying The VHS of The Simpsons, analyzing its intricate references and in-jokes. His influences included Chris Rock and the sketch show Goodness Gracious Me, which helped him see comedy as a viable path for someone of his background. "Until then, the only people I'd seen do comedy were either white or African American. You see a bunch of Indians doing it, you think: Oh, this is viable for me." Kumar's early career involved temping while struggling to make inroads in comedy, buoyed only by "the persistent encouragement of my friends." His big break came in 2015 when his fourth fringe show was nominated for an Edinburgh comedy award, followed by regular TV appearances and eventually becoming a household name after joining The Mash Report in 2017.The Impact of a Progressive Voice in ComedyKumar's outspoken progressive politics made him both celebrated and controversial. His appearances on Question Time prompted social media abuse, and figures like Piers Morgan and Andrew Neil criticized him for an "anti-British" episode of Horrible Histories. Despite these controversies, Kumar believes his involvement in culture wars ultimately did more harm than good. "It's a fucking relief. It didn't do anybody any good; me being in the conversation didn't benefit any of the causes that I was passionate about. I worry sometimes that it actually actively hindered them." Despite this, his influence has grown internationally, with The New York Times suggesting he might be "the angry progressive standup the US badly needs." His cross-generational appeal has also expanded, with audiences ranging from 14-year-olds to septuagenarians, reflecting his ability to connect with diverse audiences through his blend of political commentary and personal vulnerability.Anger and Authenticity in a New Era of ComedyAs he approaches his 40s, Kumar continues to refine his approach to comedy that balances anger with authenticity. He has been open about his mental health struggles, including diagnoses of PTSD and ADHD, which inform his work. His upcoming tour "Angry Humour from a Really Nice Guy" suggests a continued commitment to comedy that challenges both audiences and the industry itself. Despite his success in the US, where he performed his new show and appeared on Have I Got News for You, Kumar's material remains rooted in UK concerns, with American audiences showing enough interest in British politics to appreciate his takes on figures like Angela Rayner. As he continues to navigate the complexities of comedy that both entertains and provokes, Kumar remains committed to what he sees as the essential role of comedy in holding power accountable, even when it means making enemies in the process.

The Pavlovian Paradox: Mosquitoes Learn to Associate DEET with FoodFor decades, the efficacy of DEET (N,N-diethyl-meta-toluamide) has been attributed solely to its chemical properties, which are believed to either repel insects or block their ability to detect humans. However, a new study led by Professor Claudio Lazzari from the University of Tours suggests a more complex behavioral interaction. The research indicates that mosquitoes can learn to associate the scent of DEET with the presence of a blood meal, effectively turning a repellent into a lure through a process similar to Pavlovian conditioning.Experimental Evidence: From Repellent to LureThe study, published in the Journal of Experimental Biology, involved trapping mosquitoes and presenting them with warm blood that was just out of reach. The insects were simultaneously exposed to DEET. The results demonstrated a significant shift in behavior:Trained Group: 60% of mosquitoes that fed while exposed to DEET subsequently attempted to bite when exposed to the repellent alone.Control Groups: Significantly lower percentages were observed in untrained insects (17%) and those with prior exposure to DEET alone (13%).In a real-world test, nearly 60% of the trained mosquitoes attempted to bite a researcher's DEET-treated hand, whereas untrained mosquitoes universally targeted the untreated hand.Redefining Insect Control StrategiesThis discovery represents a significant shift in our understanding of how repellents work. It suggests that the reaction to DEET is not merely a chemical aversion but can be modified by experience. Experts, including Dr. Nina Stanczyk of ETH Zürich, emphasize that while the learning ability of mosquitoes is impressive, the implications for public health are nuanced. The study highlights that repellents may function differently depending on the context of the mosquito's previous interactions with humans.Future Outlook for TravelersDespite the alarming findings, experts urge travelers not to abandon DEET. The consensus is that this phenomenon occurs under specific laboratory conditions and is unlikely to happen frequently in the wild due to the variability of repellents encountered during different blood meals. The key takeaway for the future is the importance of consistent application. As noted by the researchers, the risk of association is highest when the repellent starts to wear off, reinforcing the need for regular reapplication to maintain protection.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Call for Tax Cuts Wes Streeting has called for national insurance tax cuts for businesses, and for the government to drill for oil and gas in the North Sea. The former health secretary and Labour leadership candidate told the Sunday Times there should be a “targeted reduction” of employers’ national insurance contribution as a way to “actively incentivise” hiring, particularly of young people. The Impact of National Insurance Rate Increase In 2024, the rate of national insurance paid by employers was increased from 13.8% on each employee’s salary to 15%. The starting threshold it applied to was lowered from £9,100 to £5,000. The measure aimed to raise £25bn a year, but businesses said it disincentivised hiring lower-paid and part-time staff. Youth Unemployment Concerns A report this week by the former cabinet minister Alan Milburn said a lack of hospitality jobs was contributing to high youth unemployment in Britain. It pointed to a halving of vacancies in the hospitality industry over the past four years alone. Analysis shows Britain has the third-highest rate of 16- to 24-year-olds who are not earning or learning among rich European countries. The Government's Response Pat McFadden, the work and pensions secretary, suggested he disagreed with this view. Speaking on Sky News on Sunday morning, he defended the government’s record, saying that businesses already did not have to pay employers’ national insurance for workers under 21. The Future of North Sea Drilling There has been a debate within Labour about whether to grant drilling consents for the giant oil and gas fields Rosebank and Jackdaw. Though there was a commitment not to give out any more licences for fossil fuels in Labour’s manifesto, there is a loophole that could be exploited; Rosebank and Jackdaw were given exploration licences by the previous Conservative government. They just need consent to drill. Ed Miliband's Decision Ed Miliband, the energy secretary, is due to make a decision on these oil and gas fields in coming weeks. He, along with the North Sea Transition Authority, have to decide whether the drilling would be consistent with the UK’s climate commitments.

The Connection to Nature As a recent study revealed almost half of UK adults now spend less than three hours a week in natural settings such as gardens, parks, fields or woods, we asked readers to tell us about what being outside means to them. Personal Stories of Healing The replies – heartfelt and passionate – came flooding in, with some admitting they just did not have the words to say how important it is. “It’s my happy place, my therapy and a reason to slow down and pause during my busy week,” wrote Hannah Powell from Perrywood garden centres. “I HAVE to look at plants every day. I notice every change in the garden. I sit facing the garden for my breakfast. I look out for nature on the way to work (recently seeing a little owl, red kites, foxes, hares, and more). It helped me get better when I had burnout and FND in London. I wouldn’t (couldn’t) be without it.” The Science Behind Nature's Benefits David Lynch esaid about his love of being outside. “Anxiety levels drop, all worldly concerns are put in perspective and [I] feel younger.” He agreed with others that there was plenty of recent science explaining the health benefits, but added: “I also read about ancient wisdom of Buddhism, which advocates solitary time in nature. All sources uphold the truth that better connection with nature brings better self-awareness and increased sensitivity to the needs of our ecosystem, plus better connection with each other.” The Impact on Mental Health Isabel Romaniw, who is working towards becoming a forest bathing guide, wrote passionately about the basic human need to be outside and to connect with nature. “We are animal, a simultaneously ordinary and yet utterly remarkable part of the great, miraculous tapestry of life on Earth. We have done much to shape our world and influence the fates of almost all other species we share our world with, but we must remember that we are but a tiny chapter, perhaps a footnote, in the ongoing story of the universe, in order to start to heal the damage and repair our relationships with ourselves, with each other, with our other-than-human kin, and with our one precious home.” For Romaniw, as for many others, our disconnection with nature is closely linked to “the worsening physical, mental and spiritual health crises that seem to be going on”. Cherished Memories of Nature Many of you had wonderful memories of times outside. “I was a sickly, pasty, shy, anxious kid,” wrote Mat Jordan. “In the early 70s my parents couldn’t afford to take us to the seaside one year so we went camping in the Peak District instead. It was a revelation. I absolutely loved it. The landscape and dry-stone walls of the white peak are still a favourite, although I spent some years in my 20s living in the Lake District too. One of my favourite memories is driving out of Sheffield into the Peaks with my then baby son to get him to fall asleep and still being awe-struck at the beauty on our doorstep.”

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."